MEDICAL CANNABIS AND AUTISM SPECTRUM DISORDER: GASTROINTESTINAL AND DIETARY IMPLICATIONS IN A GROUP OF CHILDREN IN MACAPÁ - AP
Medicinal cannabis; autism spectrum disorder; food selectivity.
Autism Spectrum Disorder is a multifactorial brain development disorder with a strong genetic basis, encompassing several conditions with apparently different phenotypes across three levels of support. The WHO estimates that one in every hundred children is diagnosed with ASD worldwide and that there is a higher prevalence in boys, with a ratio of 3:1 currently. Studies show that, in addition to changes in cognition, behavioral manifestations and difficulties in communication, a variety of gastrointestinal dysfunctions and symptoms such as constipation, abdominal pain, diarrhea, gas and vomiting can have a very variable prevalence in children with ASD compared to neurotypical children. Furthermore, children with ASD are five times more likely to develop eating difficulties associated with food selectivity than children without ASD. In this context, medicinal cannabis oil has been widely used as a therapeutic drug accessory in the management of autism and its comorbidities in Brazil. Its main components are the cannabinoids Δ9-tetrahydrocannabinol (Δ9-THC) and Cannabidiol (CBD). Therefore, we sought to verify the effectiveness of this product for pediatric patients aged 3 to 10 years with autism, in the city of Macapá and region - AP, with the following objectives: to characterize the nutritional profile of the studied population, monitor behavioral changes related to food, identify the presence of gastrointestinal symptoms and compare the effects of the compounds used among the age groups of the children. The method used was structured questionnaires and dietary scales applied at two different times: before the use of the oil and three to four months later. The children in the study used three types of oil, all with CBD: broad spectrum, full spectrum and isolated CBD. The results showed a sample with 77.78% of boys and 22.22% of girls, with the majority having a nutritional diagnosis of eutrophy. Few children presented gastrointestinal symptoms. Rigid behaviors, mealtime skills, and food selectivity were more influenced by the use of the oil, and children over 6 years of age had a higher average for food selectivity when compared to those under 6 years of age. Thus, research with medicinal Cannabis in the pediatric population shows itself to be a promising object of study, taking into account the positive effects on the disruptive behavior of patients with autism, the possibility of reducing conventional psychotropic drugs, and the few adverse effects reported by users.
Keywords: medical cannabis; autism spectrum disorder; food selectivity.